Our pivotal phase 3 trial of aglatimagene besadenovec (CAN-2409) in localized prostate cancer is now published in @TheLancetOncol. 80.4% of treated patients achieved pathological complete response in 2-year biopsies vs. 63.6% on placebo.
https://t.co/BZygLAfJX0
$CADL
Kyle Donahue's 5-year journey with glioblastoma, featured in @ParadeMagazine, shows the potential of innovative treatments. After enrolling in our linoserpaturev (CAN-3110) trial, her tumors shrank and she’s regained much of her life.
https://t.co/CxVl1UpET6
#Glioblastoma $CADL
We are heading to the Jefferies Global Healthcare Conference in New York, sharing updates across our pipeline in prostate cancer, NSCLC, glioma, and our enLIGHTEN™ Discovery Platform.
https://t.co/NQu8hz499h
@paulpetertak#Biotech#Biopharma $CADL
We’ll be in Chicago for @ASCO!
Our team is available for meetings — reach out to connect and hear updates on our pipeline.
https://t.co/BFaFPDOCH7
#ASCO26#Oncology#CancerResearch $CADL
Our CTDO Seshu Tyagarajan, Ph.D., discusses the analytical and validation work underpinning our BLA submission for aglatimagene besadenovec with @Lifesci_Connect, including our in-house QC capabilities and potency testing strategy.
https://t.co/qXhOpuvme8
#Biotech $CADL
On #ClinicalTrialsDay, we are grateful to the patients, investigators, and healthcare professionals driving progress in cancer care.
Learn more about our clinical programs: https://t.co/jn4xYQnmSy
#CancerResearch#Immunotherapy $CADL
Our CEO @paulpetertak is presenting at the Stifel 2026 Virtual Targeted Oncology Forum, sharing updates across our pipeline in prostate cancer, NSCLC, and recurrent glioma.
https://t.co/NQu8hz499h
#Oncology#Biotech $CADL
Announced Today - New extended follow-up data from our phase 3 trial of aglatimagene besadenovec (CAN-2409) in localized prostate cancer presented today at #AUA26.
Details here: https://t.co/RdMR2BsD34
#ProstateCancer#Immunotherapy $CADL
Today we announced our Q1 2026 financial results and provided corporate updates on our development programs.
Full details: https://t.co/U6jhHrN7Kx
$CADL
Proud to see our Chief Regulatory Officer Susan Stewart, J.D., spotlighted in @RAPSorg 50 for 50, honoring outstanding regulatory professionals for its 50th anniversary. Her expertise continues to be invaluable in guiding our regulatory strategy at Candel.
https://t.co/wicCc1Kcr3
This #NationalCancerResearchMonth, we are proud to be advancing multimodal viral immunotherapies across prostate cancer, NSCLC, and recurrent glioblastoma, with key milestones ahead in 2026.
https://t.co/liFL6tjiA0
#CancerResearch#Immunotherapy $CADL
We are heading to #AUA26!
Join us for new extended follow-up data from our phase 3 trial of aglatimagene in localized #prostatecancer, presented by Dr. Mark Garzotto in a plenary session.
Visit our booth to connect with our team.
https://t.co/E8KjXJHmrz
@AmerUrological
We will host a conference call on May 15 to discuss extended phase 3 data for aglatimagene besadenovec in localized #ProstateCancer, with thought leaders Dr. Daniel George, Dr. Neal Shore, and Dr. Jonathan Tward.
Registration details: https://t.co/MGG9pj7lkF
#AUA2026 $CADL
At #BioEquityEurope, our CEO @paulpetertak presented phase 2 data for aglatimagene in advanced NSCLC.
50% of patients survived beyond 24 months despite prior immune checkpoint inhibitor failure, with a long-term survival tail supporting phase 3 initiation.
@BioCentury#CADL
We are presenting at BioEquity Europe 2026 in Prague!
Connect with our team to learn more about our viral immunotherapy pipeline across prostate cancer, NSCLC, and glioma.
https://t.co/DAhqieJDGT
@paulpetertak@BioCentury#ProstateCancer#Immunotherapy $CADL
Our CEO @paulpetertak, M.D., Ph.D., and CTDO Seshu Tyagarajan, Ph.D., discuss our sprint to BLA submission for aglatimagene besadenovec (CAN-2409) with @Lifesci_connect, covering our partner-led manufacturing strategy and commercial readiness.
https://t.co/SxtMFIWgkS
$CADL
Today we announced a commercialization agreement with @EVERSANA to support potential U.S. launch of aglatimagene besadenovec (CAN-2409) for localized #ProstateCancer, ahead of our planned BLA submission in Q4 2026.
https://t.co/roqHSI0g4X
$CADL
We’re attending @USAIC's 20th Annual BioPharma & Healthcare Summit in Boston this Thursday, joining global leaders in biopharma and healthcare innovation.
@paulpetertak#USAIC26#Biopharma $CADL